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ABSTRACT
Objective: To give academic researchers, government officials, and industry scientists an opportunity to assess the state
of pediatric psychopharmacology and identify challenges facing professionals in the field. Method: Increased federal
spending and the introduction of pediatric exclusivity led to large increases in pediatric psychopharmacology research in
the 1990s. Despite the increase in research, concerns exist about methods and incentives for making new medications
available for use in pediatric psychiatric disorders. In recognition of these concerns, the Duke Clinical Research Institute
held a roundtable in September 2004. Participants from the National Institutes of Health, regulatory agencies, academia,
and the pharmaceutical industry spoke about the effects of government regulations such as the U.S. Food and Drug
Administration Modernization Act and the Pediatric Research Equity Act on pediatric research from academic, clinical,
and industry perspectives, and bioethical considerations of such research. Conclusions: To ensure development of
new drugs for treating psychiatric disorders in children and adolescents, we must address the challenges posed by the
regulatory environment governing pediatric psychopharmacology research. Strategies were identified for improving the
evidence base for psychopharmacologic interventions in youth before widespread use and for more effectively defining a
research agenda for the future. J. Am. Acad. Child Adolesc. Psychiatry, 2006;45(3):261Y270. Key Words: pediatric
psychopharmacology, pediatric depression, psychopharmacology trials, Pediatric Research Equity Act, Best Pharma-
ceuticals for Children Act.
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In the past 15 years, efforts by government, academia,
and the pharmaceutical industry have yielded numerous
advances in pediatric psychopharmacology. Some of the
more evident examples of progress include the estab-
lishment of infrastructure for pediatric psychopharma-
cology research (March et al., 2004c; Research
Unit on Pediatric Psychopharmacology Anxiety
Study Group, 2001), government-funded comparative
treatment trials of medications and psychotherapy
(March et al., 2004b; MTA Cooperative Group,
1999; Pediatric OCD Treatment Study Team,
2004), U.S. Food and Drug Administration (FDA)
approval of attention-deficit/hyperactivity disorder
(ADHD) medications developed specifically for chil-
dren, and regulatory changes designed to encourage
psychopharmacology trials in youth, including
the FDA Modernization Act (FDAMA), the Best
Pharmaceuticals for Children Act (BPCA), the Pedi-
atric Research Equity Act (PREA), and similar
legislative efforts outside the United States (Vitiello
et al., 2004).
HISTORICAL PERSPECTIVE
In general, research and practice in child and ado-
lescent psychopharmacology have come on the heels
of progress in adult psychopharmacology, with many
compounds quickly attaining wide use in children
and adolescents despite little or no randomized
evidence on which to base clinical practice. Historically,
pharmaceutical companies have demonstrated modest
interest in developing new psychopharmacological
treatments for patients younger than 18 years (Buck,
2000). The exceptions were new formulations of
stimulants (methylphenidate and amphetamines) and
a nonstimulant (atomoxetine) as treatments for
ADHD, and clomipramine and the selective serotonin
reuptake inhibitors (SSRIs) as treatments for obsessive-
compulsive disorder.
Until the late 1990s, the National Institute of
Mental Health (NIMH) funded most of the research
in pediatric psychopharmacology, including almost
all of the placebo-controlled trials of tricyclic anti-
depressants and most studies of stimulant medications
in ADHD (Vitiello et al., 2004). NIMH funded
the first placebo-controlled trial of fluoxetine that
showed efficacy in pediatric depression (Emslie et al.,
1997), and industry provided support through inves-
tigator-initiated research grants but seldom spon-
sored trials to test the efficacy of medications in
children until the mid-1990s, when several companies
began to examine stimulants as treatments for ADHD
(see Swanson et al., 1998, 1999; Wigal et al., 1998).
The pharmaceutical industry_s low interest in testing
medications in children pertained to most types
of medication, not only psychotropic drugs.
EFFECTS OF LEGISLATION AND
MARKETING EXCLUSIVITY
During the mid-1990s, the off-label use of medica-
tions in children was widespread enough to spur
legislation that, via financial incentives, would acceler-
ate the availability of products licensed for use in
children and adolescents without unduly delaying the
availability of these products for adults (U.S. Congress,
1997). The legislation, FDAMA_s pediatric exclusivity
provision, offered 6 months of additional marketing
exclusivity (equivalent to extension of patent protection
by 6 months) for a drug product in return for the
company_s conducting pediatric studies on that drug.
This powerful incentive changed the landscape of
pediatric pharmacology research. Since then, most
pediatric clinical trials of psychotropic drugs have been
funded by industry, and several pharmacokinetic
studies have been completed or are in progress.
The process may be initiated by a sponsor requesting
that the FDA issue a Written Request or by the FDA
issuing a Written Request of its own volition to the
sponsor. By the end of January 2005, 364 requests for
pediatric studies (14% of these for neuropsychiatric
drugs) had been proposed by industry. Of those
proposals, the FDA issued Written Requests for 298
products (13% of which were for neuropsychiatric
drugs; U.S. Food and Drug Administration, 2004c).
Thus far, 12 drugs (Adderall XR, Concerta, buspirone,
citalopram, venlafaxine, fluvoxamine, paroxetine, flu-
oxetine, mirtazapine, nefazodone [now withdrawn],
atomoxetine, and sertraline) (U.S. Food and Drug
Administration, 2000a) used to treat psychiatric
disorders in children have been granted additional
marketing exclusivity under this program.
Similar regulations are being pursued in Europe
that will provide incentives to industry by giving
patent-life extension for pediatric medication research.
Off-patent products being developed specifically for
children will be eligible for a Pediatric Use Marketing
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Authorisation (PUMA) that will ensure 10 years of
marketing protection. Although the European Union
Commission has agreed on a draft regulation, formal
finalization will probably take an additional 1 to 2 years
(European Commission, 2004). Furthermore, the
International Conference on Harmonisation (ICH)
guideline E11, ‘‘Clinical Investigation of Medicinal
Products in the Pediatric Population,’’ has been agreed
on by the three ICH regions: Japan, the United States,
and the European Union. Guideline E11 covers general
issues, such as the ethics of conducting trials in chil-
dren, definition of pediatric age groupings, timing
of pediatric drug development in relation to
drug development in adults, and the possibility for
extrapolating efficacy data from adult studies. More-
over, the Committee for Medicinal Products for Human
Use and the European Medicines Agency are developing
guidelines for the types of trials needed to assess efficacy
and safety of medicinal products in children (European
Medicines Agency [EMEA] Guidelines, 2000).
SPECIFIC CHALLENGES
Drug Safety
Controversies flare up over rare but salient adverse
events in the area of child psychopharmacology.
Examples include hepatic failure with pemoline treat-
ment (Shevell and Schreiber, 1997), sudden unex-
plained deaths when methylphenidate and clonidine are
used in combination, and suicidality and suicidal
ideation during treatment with SSRI and serotonin-
norepinephrine reuptake inhibitor (SNRI) antidepres-
sants (U.S. Food and Drug Administration, 2004b).
To establish a statistical link between treatment and
rare events would require impractical sample sizes, but
improved response to these types of controversies is
required. New ways are needed to address potential
adverse events that are unlikely to be evaluated by
traditional clinical trials and statistical approaches. For
example, provisions for long-term follow-up (which is
expensive) and knowledge of statistical methods for
evaluating self-selected groups (e.g., new methods for
propensity analyses) are needed to evaluate possible
effects that emerge over time or that are the result of
early exposure to medication in the sensitive (and
vulnerable) pediatric population. Also, some adverse
effects, such as those on growth, are important in
children but not in adults because individuals who have
reached full size cannot experience growth suppression.
Long-term follow-up studies are necessary to investi-
gate these potential effects.
Data Ownership
Although the pediatric exclusivity program launched
by FDAMA is considered a success for the number of
new studies that it has generated, limitations have
emerged. For example, the ownership of data collected
during industry-sponsored studies has been an issue; the
interpretation has been that such data belong to the
sponsor, and it has been the sponsor_s decision whenVor
even whetherVto publish. When studies are published,
there is often a delay of several years between the approval
of a drug and the publication of the clinical trial data
upon which that approval is based. The results of many
studies are never published, particularly negative SSRI
trials in adolescent depression, despite eagerness on the
part of academic collaborators to do so. This problem has
been corrected, in part, by the BPCA (U.S. Congress,
2002), which mandates the posting of a summary of the
medical and clinical pharmacology reviews on the FDA
Web site, and through voluntary commitments from
industry to make the results of most clinical trials
available to the public. Written Requests themselves
remain confidential and thus not open to public
comment. Furthermore, the academic collaborators are
rarely allowed direct access to the data for more complex
or alternative analyses.
Timing of Pediatric Studies
The timing of pediatric studies under FDAMA has
also been a complex issue. Written Requests mandate the
submission of required pediatric study reports within a
specific time frame. Although these requests are designed
to provide industry ample time to complete the requested
studies, the timelines are considered overly aggressive by
some, and further time challenges may be introduced by
the internal pressures industry faces when confronting
exclusivity or patent expirations. Such time pressuresmay
favor expeditious choices in trial implementation that can
affect trial quality or may even dissuade industry from
conducting trials altogether. One result of this has been
that, in industry-sponsored pediatric psychopharmacol-
ogy development programs, acute dose pharmacokinetic
studies have many times not been completed before
initiation of efficacy and safety studies. Without
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appropriate pediatric pharmacokinetic information to
guide them, these efficacy and safety trials can meet the
requirements of theWritten Request but be conducted at
doses that are inappropriate for demonstrating efficacy or
tolerability in children and in adolescents. Recently, the
FDA began requesting that acute pharmacokinetic
studies now be completed earlier in the pediatric
development cycle, but population pharmacokinetic
studies remain rare. Thus, another limitation of
FDAMA may be that marketing exclusivity is granted
for completing the agreed-on studies, but not necessarily
for demonstrating the efficacy or safety of a drug.
After a sponsor has submitted reports in response to a
Written Request, the FDA is under a 90-day (in some
cases 60-day) statutory constraint to review the submis-
sion and determine whether the applicant has fairly
responded to the Written Request (i.e., conducted the
requested studies). This occurs before the 6-month
review of the application is completed. A 6-month
period to determine approvability for marketing is
mandated under the BPCA for review of the data and
information submitted in the pediatric studies. During
this period, the quality and meaning of the studies
themselves are evaluated, the action on the studies
(approval, approvable, nonapproval) is decided, and,
ideally, labeling changes are negotiated with the sponsor.
Some question whether these time frames allow adequate
review. The justification for enacting 6-month review
times has been to speed drugs to patients, but because
drugs approved for adult use are routinely prescribed to
children, this situation does not generally apply in
pediatric psychopharmacology. Indeed, the opposite
situation prevails: These studies have typically not been
completed until years after the medications were made
available for adults. Although this is ethically acceptable
in cases in which there is already an approved pediatric
treatment available, all too often pediatric studies for
important treatments are begun late in the drug develop-
ment process or in response to a Written Request, if at
all. As a result, such drugs are often widely prescribed to
youth, without evidence of safety or efficacy from
controlled studies. Although the incentives provided
under the FDAMA have motivated some industry
sponsors to conduct additional pediatric studies, the
small number of treatment outcome studies in pediatric
patients relative to those in adults, the long lag between
the time that a drug is introduced for adults and the
pediatric trials are conducted, and the fact that pediatric
studies are typically conducted in trial populations and
with designs that do not match the realities of clinical
practices sharply reduce their value to decision makers
making choices about patient care.
Insufficient Incentive?
To justify the investment in research necessary to
develop a new drug, industry must carefully assess the
size of the potential market for that drug. A recent
estimate for the cost of new drug development is $800
million (DiMasi et al., 2003). Within pediatric
psychopharmacology, the most prevalent disorder is
ADHD, which is estimated to affect about 3% to 5% of
children and adolescents. This prevalence has resulted
in a market for the pharmaceutical industry worth $1.4
billion/year in 2002 and projected to increase to $3.3
billion by 2012 (Garland and Kirkpatrick, 2004).
Given that other pediatric mental disorders are less
common, they are unlikely to emerge as plausible
targets for drug development in their own right because
of the high costs of drug development and the
significantly smaller prospective market. Thus, exclu-
sivity under the FDAMA and now the BPCA is the
primary incentive for industry to study treatments for
mental disorders in children and adolescents.
Despite the many studies generated by the FDAMA,
only about one third of drugs used in children have
pediatric prescribing information in the product label
(Roberts et al., 2003). In psychopharmacology, of the
12 products granted exclusivity, the studies resulted in
additional indications for just four products: sertraline
for pediatric obsessive-compulsive disorder, and Adder-
all XR, Concerta, and atomoxetine for adolescent
ADHD. The latter three were already intended for use
in childhood ADHD and the labeling was simply
expanded to include use in adolescents. For fluvox-
amine and fluoxetine, the studies that resulted in
exclusivity and pediatric use indications were initiated
before the FDAMA. Otherwise, exclusivity studies of
psychopharmacological agents have, for the most part,
resulted in labeling language noting that clinical studies
did not support a pediatric indication; however, it is
important to note that the risk of suicidality associated
with antidepressant use in children was first identified
from a data set composed primarily of studies done for
exclusivity. Thus, it seems that the current systems and
incentives are insufficient to ensure that psychophar-
macological drug products will be developed for
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children and adolescents even when those drugs are
intended to be marketed for adult use.
Complicating this situation is the fact that some of
the drugs that are effective in adult disorders (anti-
depressants being the most studied) do not appear to
have the same efficacy in children. Whether this is
because childhood disorders are somehow different
from the adult versions, because placebo or nonspecific
responses are different in children (making it harder to
discriminate drug effect), or because the immature
CNS responds differently to pharmacological influ-
ences, the result is that many pediatric clinical trials
conducted for the purpose of gaining additional
marketing exclusivity are not providing clinicians with
data that support the use of these drugs in their
pediatric and adolescent patients. If there are pharma-
cological treatments that are effective mainly in the
pediatric but not the adult population, what can be
done to increase the likelihood that the pharmaceutical
industry will want to develop them? Can we find
another system for promoting the discovery of drugs
that are effective in this population?
RECOMMENDATIONS
Greater emphasis must be placed on safety out-
comes, such as through the use of standardized safety
assessment tools and long-term studies. Greenhill et al.
(2004) recently reported that the body-systems review
method used in the Safety Monitoring Uniform
Report Form can, by focusing on individual organs,
help detect additional medically important adverse
events missed by the methods typically used in
industry trials, such as the spontaneous reporting or
general inquiry elicitation methods. Moreover, stan-
dardized methods of collecting safety data could
facilitate pooling of data from multiple clinical de-
velopment programs, enabling safety assessments, such
as one conducted by the FDA in 2004 evaluating self-
harm in children and adolescents treated with anti-
depressant drugs, to provide the sample size needed
to detect uncommon adverse events (Vitiello et al.,
2003). In addition, because some side effects, such
as attenuation of growth, are important in children
but not in adults (because adults have reached full
stature, they cannot show growth suppression), long-
term studies are needed to evaluate possible effects
that emerge over time or are caused by early exposure
to medication during development.
Practical Clinical Trial Networks
In addition to establishing efficacy, future studies
ideally should provide long-term evidence of safety
in children and adolescents and also include relevant
populations in terms of comorbidities and concurrent
medications. However, typical efficacy studies, which
exclude most comorbidity, are relatively brief and
are too small to identify subgrouping variables or other
than common adverse events. Large, simple effective-
ness trials conducted on practical clinical trial (PCT)
networks offer a platform on which to deploy
standardized adverse event reporting measures, allow
identification of moderators of treatment outcome,
and can be used to establish safety databases to define
the risks and tolerability of drugs during short- and
long-term treatment in the pediatric population.
PCTs are typically characterized by eight key features:
a straightforward, clinically relevant question, a repre-
sentative sample of patients and practice settings,
sufficient power to identify modest but clinically relevant
effects, randomization to protect against bias, clinical
uncertainty regarding the outcome of treatment at the
patient level, assessment and treatment protocols that
employ best clinical practices, simple and clinically
relevant outcomes, and limited subject and investigator
burden (March et al., 2005). Implementing the PCT
model in psychiatry will require construction of a stable
network of clinical investigators as well asmethodological
innovation in assessment, treatment, data management,
site management, and data analytic procedures. One
example of the PCT model is the Child and Adolescent
Psychiatry Trials Network, which is funded by the
NIMH and is a collaborative effort of the Duke Clinical
Research Institute and the American Academy of Child
and Adolescent Psychiatry (March et al., 2004c).
PCTs can also help satisfy the need for improved
drug safety assessments by supplementing pharmacoe-
pidemiological studies of large naturalistic databases,
such as those collected and maintained by the FDA
and health maintenance organizations. Passive surveil-
lance, such as FDA_s MedWatch reporting system and
the Adverse Event Reporting System database, although
suitable for detecting rare events that are severe and
unexpected, may not be suitable for detecting drug
effects for commonly reported adverse events. In
addition, passive reporting systems do not estimate
the event incidence rate relative to control or active
comparators, which benefit from systematic adverse
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events assessments (Greenhill et al., 2004). Health
maintenance organizations, Medicaid, and databases
such as the General Practice Research Database offer
the possibility of longitudinal assessments that allow for
the testing of specific hypotheses (Rodriguez et al.,
2001). In pediatric psychopharmacology, the General
Practice Research Database has recently been used to
examine the relationship between suicidal behavior and
antidepressant treatment (Jick et al., 2004).
RiskYBenefit and Placebo-Controlled Trials
As the pediatric psychopharmacology field has
become more prominent, so have issues involving
the ethical context in which trials are conducted
(Derivan et al., 2004; March et al., 2004a). For
example, 21 CFR 50, Subpart D, has extended
the protections afforded to children in federally
sponsored clinical trials (first codified in 45 CFR 46,
Subpart D) to all clinical trials involving FDA-regulated
products. Subpart D contains four categories of
research based on the degree of risk (i.e., minimal or
greater than minimal) and whether there is the prospect
of direct subject benefit. Most clinical trials involving
children are classified under 21 CFR 50.52, which
is research involving greater than minimal risk but
presenting a prospect of direct benefit to the individual
subjects. Under Section 50.52, an institutional review
board must determine that the riskYbenefit relationship
of the research is at least as favorable to the subjects
as that presented by available therapeutic alternatives.
Such research must be in clinical equipoiseVthat is,
there must be genuine uncertainty on the part of the
expert medical community as to the comparative
therapeutic merits of each arm of the clinical trial.
Achievement of clinical equipoise can be particularly
problematic in placebo-controlled, randomized con-
trolled trials (RCTs; Derivan et al., 2004; March et al.,
2004a). In pediatric research, the riskYbenefit relation-
ship must be at least as favorable as that of alternative
treatments (Section 50.52). Therefore, investigators
and institutional review boards must justify placebo
controls with consideration of direct subject benefit
and available alternatives. If a pediatric study cannot
meet the requirements of Section 50.52, then it must be
considered under additional Subpart D categories,
which contain more stringent approval requirements.
Clearly, the ethical basis for conducting research in
children is different from that for adults and remains
an evolving process (Fost, 2001; Greenhill et al., 2003).
Recent trends point to increasingly restrictive elements,
which will make the use of placebo exceedingly dif-
ficult, thus potentially limiting the number of drug
candidates that can be adequately studied. For example,
under the most restrictive assumptions, once the first
drug in a class is shown to be superior to placebo, it
could be nearly impossible to conduct similar trials with
additional drugs from that class; indeed, once any
effective treatment has been shown for a given
condition, it may become difficult to study any other
treatments for that condition. At the same time, it is
important to recognize the value of a placebo arm in a
clinical study evaluating the safety of an investigational
drug. Thus, reasonable voices argue that properly
designed placebo-controlled trials remain necessary,
ethical, and feasible but may require innovative research
designs; greater involvement of consumers in planning
and implementing research; flexibility by industry,
academia, the National Institutes of Health, and
regulatory agencies to act in partnership; and, where
needed, concomitant use of evidence-based psychoso-
cial services (March et al., 2004).
Alternatives to Classic RCTs?
Although the classic placebo-controlled RCT
appears to be increasingly more difficult to conduct
in this population for reasons of ethics and feasibility,
the implementation of the BPCA (U.S. Congress,
2002) and PREA (U.S. Congress, 2003) will result in
more placebo-controlled RCTs in children and adoles-
cents. Because Subpart D was not written with any
focus on placebo controls, justification of placebo
control will require collaboration of investigators and
institutional review boards to use placebo when it is sci-
entifically, medically, and ethically justified (Derivan
et al., 2004; March et al., 2004).
In addition, before effectiveness trials on PCT
networks, placebo-controlled efficacy studies emphasiz-
ing mechanisms of treatment response may be required
to optimize the use of medication, even those with long
clinical histories, as recent examples from the pharma-
cokinetic/pharmacodynamic studies of stimulant med-
ication have demonstrated. This approach characterized
the development of most of the new formulations of
stimulants for the treatment of ADHD, with concept
studies based on highly controlled trials using the
Laboratory School Paradigm and surrogate measures
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of efficacy, before large, randomized clinical trials to
demonstrate efficacy and gain FDA approval were
conducted. In the area of stimulants, small comparison
trials are being conducted to distinguish the many
new formulations (Concerta versus Metadate; Swanson
et al., 2004) and classes of medications (Adderall XR
versus atomoxetine) in tightly controlled experimental
designs funded by industry. Head-to-head trials of these
medications in large, real-world samples have yet to be
conducted, and, as a result, clinical decision makers
cannot be sure of their relative value and who benefits or
has unacceptable adverse events. Hence, there is a need
for large PCTs comparing the new psychostimulant
preparations and also the new nonstimulant atomox-
etine, perhaps to older-generation immediate-release
stimulant preparations.
In some cases, child and adolescent psychopharma-
cology researchers may need to employ alternatives to
the classic RCT that has been the standard for
psychopharmacology drug development for nearly 50
years. Alternative designs may include active controlled
noninferiority (or superiority) trials, adaptive designs,
group sequential designs, patient preference designs,
and equipoise-stratified designs. Moreover, although
psychopharmacology research (particularly in the
development of new drugs) has historically either
excluded or limited psychotherapy during a trial, the
role of behavioral and other approaches in pediatric
practice must be evaluated alone and in combination
with medications (Franklin et al., 2003; Treatment for
Adolescents With Depression Study Team, 2003). If
behavioral interventions can influence the effects of
drug treatment, then this could have important
implications for both the efficacy and safety of drug
treatment. Considering the numerous failures (particu-
larly with antidepressant drugs) to show benefits of
drug treatment alone in this population, we must be
open to studying other approaches.
CONCLUSIONS
Historically, the pharmaceutical industry and acade-
mia have not shared an agenda for research in children
and adolescents. Despite the legislative changes of the
past 8 years, which have resulted in an obvious interest
on the part of industry, the academic and industry
research agendas in pediatric psychopharmacology are
poorly aligned. The most likely cause for this is that
the two enterprises are working toward different
objectives. Industry, whose agenda is driven by the
desire to meet regulatory requirements to include
information in the drug label, focuses on meeting
the FDA_s issuance of Written Requests, which have
called for RCTs of widely used medications versus
placebo, in relatively homogeneous populations, for
single disorders, and powered to test for efficacy rather
than safety. Having first established efficacy where
appropriate, clinical decision makers are seeking active
comparator and treatment addition trials in trial
populations that resemble real-world clinical practice.
A more satisfactory approach may be for industry
and academia to partner with the FDA to pursue
Written Requests that meet the needs of clinical decision
makers as well as satisfy the FDA_s desire for placebo-
controlled designs.
The dialogue between these parties needs to be more
focused on the needs of children and adolescents as
well as those who treat them. Although no one would
expect the pharmaceutical industry to pursue a research
agenda contrary to the interests of its shareholders, the
incentives that are currently in place have thus far been
insufficient to improve the pharmacological treatment
of children and adolescents with psychiatric disorders in
a meaningful way. This could be rectified by establishing
a forum wherein the needs of this patient population
are clearly articulated in the strategic thinking of those
defining the research agenda for industry. Ideally,
incentives would exist within the industry to pursue
the child and adolescent population as a strategic target
in and of itself. Although academic experts will continue
to rely heavily on industry for funding, mechanisms are
needed whereby that reliance does not further tilt the
academic agenda toward the industry agenda or create
real or apparent conflicts of interest. In addition,
academic experts who accept financial support from
industry must maintain their own integrity and protect
the credibility of the academic enterprise.
Communication has been a challenge not only
between academia and industry but also among
pediatric psychopharmacologists. Although the pediat-
ric psychopharmacology research community is not
large, there appears to be difficulty in exchanging ideas
adequately within the field, and even less systematiza-
tion is in place to disseminate new knowledge. Inter-
action between child and adolescent psychiatry with
the broader field of pediatrics is also limited, although
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pediatricians increasingly treat mentally ill youths
with psychotropic medications. Moreover, child and
adolescent psychiatry has been rather unsuccessful in its
communication with the public, despite the existence
of patient- and consumer-oriented organizations with
sincere commitments to the welfare of the child and
adolescent population. The recent controversy sur-
rounding the use of antidepressant drugs in this patient
population highlights these difficulties.
Better communication strategies are needed. There
have been many meetings of stakeholders since the early
1990s (see, e.g., March et al., 2005). Although these
meetings have helped move the field forward to some
degree, there is a general sense that the momentum
is weak. More dialogue is needed, both within the child
and adolescent psychiatry community, as well as with
pediatrics and primary care. Direct involvement of
patients and their families in psychopharmacology
research, in ways other than as research subjects,
will enhance the dissemination of information to the
public. It is suggested that patient representatives
be included in the process of study design and in
some way participate in the evaluation of data, perhaps
through a relationship to data and safety monitoring
boards. A stronger voice for pediatrics that crosses
therapeutic areas and is to some extent separate from
adult drug development programs within the pharma-
ceutical industry would be desirable.
The research agenda is itself uncertain. For example,
the landscape of mental health services is changing
rapidly (Safer, 1997). More children are receiving drug
treatments (see, e.g., Zito et al., 1999, 2000) and fewer
receive psychosocial treatments (Hoagwood et al.,
2000). It is usually assumed but not proven that higher
quality, evidence-based treatments delivered by provi-
ders who are current with respect to best practice
standards would result in improved mental health
outcomes (Guyatt et al., 2000; Weisz and Hawley,
1998). In this context, informed observers agree that
there is a conspicuous and unfortunate gap between
research and practice that reflects considerable hetero-
geneity in the type and quality of care delivered to
mentally ill youths (Szatmari, 1999). This gap provides
both the rationale and, in some sense, the method
for advancing a pragmatic clinical trials agenda.
Although clinician opinion and data from efficacy
trials, pharmacoepidemiology, and treatment guide-
lines highlight gaps in the evidence base, there appears
to be no mechanism for deciding which questions to
ask and with what priority to pursue them. To some
extent, this concern is a consequence of the commu-
nication and industry-academia alliance problems
noted above; at the least, they overlap considerably.
The agenda needs to be defined through a collabo-
rative process that includes and addresses the needs of
all stakeholders (clinicians, patients, and families,
academic researchers, industry, and government). A
mechanism is needed for deciding and prioritizing the
questions. One effective mechanism would be to
convene a National Institutes of Health Consensus
Development Conference, as was done in 1995, to
explore these issues and to help define the research
agenda (Vitiello and Jensen, 1997). To be effective
globally, however, such a conference needs to have
international participation consistent with the spirit
and intent of ICH.
For drugs being developed for adults, the pediatric
studies should occur much earlier in the development
cycle and should include more than the minimalist
approach that has been followed under current regu-
latory incentives. Incentives for conducting pediatric
studies could be revised to reward efforts that produce
useful information about safety and efficacy that can
actually guide practice. Ideally, the pediatric population
would be viewed by the pharmaceutical industry as a
target population, much like the targets currently
recognized as therapeutic areas, and drugs would be
developed for children by first intent. Some drugs could be
developed for pediatric use, although others may be for
both pediatric and adult use, and still others for use in
adults only.
The use of psychotropic medicines in children
continues to increase faster than the evidence base
supporting such use. Yet, child and adolescent phar-
macology has made significant advances in the past 15
years. In part, this is the result of regulatory incentives
provided to the pharmaceutical industry, although
careful assessment of these incentives reveals a number
of shortcomings. These shortcomings have resulted
in research that is less valuable to clinicians treating
mentally ill youths than to other stakeholders. This
situation, coupled with insufficient communication
within the pediatric psychopharmacology community
and with the public, has led to several controversies
in recent years. In the future, the research enterprise
in child and adolescent psychiatry will need to improve
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communications and focus on better meeting the needs
of pediatric and adolescent patients through improved
or refined regulatory incentives, greater attention to
drug safety, and development of innovative clinical trial
designs and methods.
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New and Lingering Controversies in Pediatric End-of-Life Care Mildred Z. Solomon, EdD, Deborah E. Sellers, PhD,
Karen S. Heller, PhD, Deborah L. Dokken, MPA, Marcia Levetown, MD, Cynda Rushton, DNSc, RN, FAAN, Robert D.
Truog, MD, Alan R. Fleischman, MD
Objectives: Professional societies, ethics institutes, and the courts have recommended principles to guide the care of children with
life-threatening conditions; however, little is known about the degree to which pediatric care providers are aware of or in
agreement with these guidelines. The study_s objectives were to determine the extent to which physicians and nurses in critical
care, hematology/oncology, and other subspecialties are in agreement with one another and with widely published ethical
recommendations regarding the withholding and withdrawing of life support, the provision of adequate analgesia, and the role
of parents in end-of-life decision-making. Methods: Three children_s hospitals and 4 general hospitals with PICUs in eastern,
southwestern, and southern parts of the United States were surveyed. This population-based sample was composed of attending
physicians, house officers, and nurses who cared for children (age: 1 month to 18 years) with life-threatening conditions in
PICUs or in medical, surgical, or hematology/oncology units, floors, or departments. Main outcome measures included
concerns of conscience, knowledge and beliefs, awareness of published guidelines, and agreement or disagreement with
guidelines. Results: A total of 781 clinicians were sampled, including 209 attending physicians, 116 house officers, and 456
nurses. The overall response rate was 64%. Fifty-four percent of house officers and substantial proportions of attending
physicians and nurses reported, ‘‘At times, I have acted against my conscience in providing treatment to children in my care.’’
For example, 38% of critical care attending physicians and 25% of hematology/oncology attending physicians expressed these
concerns, whereas 48% of critical care nurses and 38% of hematology/oncology nurses did so. Across specialties, ,20 times as
many nurses, 15 times as many house officers, and 10 times as many attending physicians agreed with the statement,
‘‘Sometimes I feel we are saving children who should not be saved,’’ as agreed with the statement, ‘‘Sometimes I feel we give up
on children too soon.’’ However, hematology/oncology attending physicians (31%) were less likely than critical care (56%) and
other subspecialty (66%) attending physicians to report, ‘‘Sometimes I feel the treatments I offer children are overly
burdensome.’’ Many respondents held views that diverged widely from published recommendations. Despite a lack of awareness
of key guidelines, across subspecialties the vast majority of attending physicians (range: 92Y98%, depending on specialty) and
nurses (range: 83Y85%) rated themselves as somewhat to very knowledgeable regarding ethical issues. Conclusions: There is a
need for more hospital-based ethics education and more interdisciplinary and cross-subspecialty discussion of inherently
complex and stressful pediatric end-of-life cases. Education should focus on establishing appropriate goals of care, as well as on
pain management, medically supplied nutrition and hydration, and the appropriate use of paralytic agents. More research is
needed on clinicians_ regard for the dead-donor rule. Pediatrics 2005;116:872Y883.
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